Recently, we discovered a bullish thesis concerning The Cigna Group from Investing With Purpose on Substack. In this article, we will provide a comprehensive overview of the bullish perspective regarding Cigna (NYSE: CI). As of September 18th, Cigna’s shares were trading at $293.76, with trailing and forward P/E ratios reported at 16.26 and 9.13, respectively, according to Yahoo Finance.
Image Source: designer491/Shutterstock.com
Cigna (NYSE: CI) has experienced a notable decline in share price, falling nearly 12% from its June highs, which has positioned it within oversold territory ahead of the earnings report due on July 31. This scenario creates a tactical “buy-the-dip” opportunity for investors. The company continues to exhibit strong fundamentals, boasting mid-single-digit revenue and EPS growth, industry-leading margins, and notable free cash flow, all underpinned by moderate leverage. With a net margin of approximately 4.5%, Cigna outperforms the managed-care average, demonstrating effective cost control and the robustness of its pharmacy benefit management (PBM). Additionally, the sustained free cash flow is supported by a conservative capital expenditure profile.
Cigna’s current valuation at around 15 times forward EPS positions the stock slightly below its peers. However, it benefits from a higher return on equity (ROE) and enhanced cash conversion capabilities, suggesting a slight discount for a fundamentally sound business. Key risks to consider include potential regulatory shifts, rising drug costs, and possible integration challenges from mergers and acquisitions. Nonetheless, catalysts such as improved earnings, margin growth, advancements in ESG practices related to value-based care, and further debt reduction could drive significant upside potential.
On the technical front, Cigna’s stock is trading below several major moving averages and within the Ichimoku cloud, indicating a bearish sentiment. However, momentum indicators like the Relative Strength Index (RSI) and Stochastic RSI hint at possible near-term recovery opportunities. Crucial support levels are around $285 to $280, with protective stops placed near the $270 mark. Conversely, resistance levels are seen between $305 and $312. A sustained recovery above the 100- and 200-day simple moving averages (SMAs) could establish a medium-term trading range between $320 and $340.
A disciplined trading strategy would involve gradually increasing positions on weakness, aiming for a short-term relief bounce, followed by a commitment to longer-term gains, reliant on the stability of Cigna’s fundamentals. In summary, Cigna represents a promising buy-on-weakness opportunity, driven by its strong valuation metrics, solid cash flow, and the promising outlook of upcoming earnings reports.
In our previous analysis, we examined a bullish thesis on The Cigna Group by Antonio Linares published in May 2025. That discussion highlighted the company’s dynamics in PBM, pricing concessions related to GLP-1, and its structural competitive advantages. Since then, Cigna’s stock has decreased approximately 6.05%, reflecting a deviation from the anticipated outcomes of the thesis in the near term. Nevertheless, the underlying premise remains intact as Cigna is still deemed undervalued, supported by its resilient fundamentals. Investing With Purpose reiterates a similar outlook, focusing on a tactical ‘buy-the-dip’ strategy.
This rewrite maintains the original HTML structure and integrates the necessary elements while presenting the information in a unique manner suitable for a WordPress platform.
